Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C]HLX208 in Healthy Subjects
NCT05841940Phase 1Completed
- Sponsor
- Henlius
- Start
- Jun 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HLX208 in solid tumor, Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD), sponsored by Henlius. Primary endpoints: Mass balance recovery of total radioactivity in urine and fecal samples, Total radioactivity in plasma PK: Cmax and 6 more. Started Jun 2023; status: completed.
02
Drugs
HLX208
03
Conditions
solid tumorLangerhans cell histiocytosis (LCH)Erdheim-Chester disease (ECD)
Beyond the preview
Go deeper on NCT05841940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05841940.